Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Viruses are being investigated as novel cancer therapies due to their ability to selectively infect and destroy cancer cells (oncolytic action).
• Immuno-oncolytic viruses leverage natural viral properties for cancer cell targeting and replication, offering a potential new class of anticancer treatments.
• Genetic modification of oncolytic viruses provides a versatile platform for developing advanced therapeutic modalities to address limitations of current cancer treatments.

Approach:

• This review focuses on the immunomodulatory functions of oncolytic viruses (OVs), a rapidly growing area of research.
• It discusses ongoing clinical studies evaluating the efficacy of immuno-oncolytic viruses in cancer treatment.
• The review explores strategies for designing these viral platforms to achieve desired immune responses and enhance existing immunotherapies.

Key Points:

• Oncolytic viruses exhibit selective oncolytic activity against malignant cells.
• Immuno-oncolytic viruses possess inherent capabilities for efficient cancer cell infection, replication, and lysis.
• Engineered oncolytic viruses serve as platforms for developing novel therapeutic strategies.
• Significant advancements have been made in understanding the interplay between cancer and the immune system, particularly concerning OVs.
• Current clinical trials are assessing the effectiveness of immuno-oncolytic viruses and optimizing their design for therapeutic benefit.

Conclusions:

• Immuno-oncolytic viruses represent a promising frontier in cancer therapy, with potential to enhance existing immunotherapeutic approaches.
• Further research and clinical development, including studies on Vaxinia, are crucial for realizing the full potential of these agents against immune-resistant cancers.